AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies
By Robert Lin, MD
Adjuvant targeted therapy already has a track record in early-stage non-small cell lung cancer (NSCLC) driven by EGFR or ALK alterations, where it has meaningfully reduced recurrence after surgery.
The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies
By Robert Lin, MD
Adjuvant targeted therapy already has a track record in early-stage non-small cell lung cancer (NSCLC) driven by EGFR or ALK alterations, where it has meaningfully reduced recurrence after surgery.
The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies
By Robert Lin, MD
Adjuvant targeted therapy already has a track record in early-stage non-small cell lung cancer (NSCLC) driven by EGFR or ALK alterations, where it has meaningfully reduced recurrence after surgery.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Early Relapse DLBCL: A Case-Based Guide to CAR T-Cell Referral, Product Selection, and Post-CAR-T Sequencing
By Vipal Durkal, MD
Early relapse diffuse large B-cell lymphoma (DLBCL), defined as relapse within 12 months of frontline therapy, should prompt evaluation for second-line CAR T-cell therapy rather than default salvage chemotherapy and transplant.
Early Relapse DLBCL: A Case-Based Guide to CAR T-Cell Referral, Product Selection, and Post-CAR-T Sequencing
By Vipal Durkal, MD
Early relapse diffuse large B-cell lymphoma (DLBCL), defined as relapse within 12 months of frontline therapy, should prompt evaluation for second-line CAR T-cell therapy rather than default salvage chemotherapy and transplant.
Early Relapse DLBCL: A Case-Based Guide to CAR T-Cell Referral, Product Selection, and Post-CAR-T Sequencing
By Vipal Durkal, MD
Early relapse diffuse large B-cell lymphoma (DLBCL), defined as relapse within 12 months of frontline therapy, should prompt evaluation for second-line CAR T-cell therapy rather than default salvage chemotherapy and transplant.
Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"
By Joshua Brandstadter, MD, PhD, MSc
Castleman disease is not one disease but a polyclonal lymphoproliferative disorder spanning a spectrum from single-lymph-node (unicentric) to widespread (multicentric) involvement, with an emerging "oligocentric" category recognized in between.
Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"
By Joshua Brandstadter, MD, PhD, MSc
Castleman disease is not one disease but a polyclonal lymphoproliferative disorder spanning a spectrum from single-lymph-node (unicentric) to widespread (multicentric) involvement, with an emerging "oligocentric" category recognized in between.
Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"
By Joshua Brandstadter, MD, PhD, MSc
Castleman disease is not one disease but a polyclonal lymphoproliferative disorder spanning a spectrum from single-lymph-node (unicentric) to widespread (multicentric) involvement, with an emerging "oligocentric" category recognized in between.
EGFR Resistance Is Heterogeneous, and That Should Change How We Study New Drugs
By Joshua Sabari, MD
Resistance to third-generation EGFR inhibitors is far more heterogeneous than the resistance patterns seen after earlier-generation drugs, and in 40-50% of patients, no single resistance mechanism can even be identified.
EGFR Resistance Is Heterogeneous, and That Should Change How We Study New Drugs
By Joshua Sabari, MD
Resistance to third-generation EGFR inhibitors is far more heterogeneous than the resistance patterns seen after earlier-generation drugs, and in 40-50% of patients, no single resistance mechanism can even be identified.
EGFR Resistance Is Heterogeneous, and That Should Change How We Study New Drugs
By Joshua Sabari, MD
Resistance to third-generation EGFR inhibitors is far more heterogeneous than the resistance patterns seen after earlier-generation drugs, and in 40-50% of patients, no single resistance mechanism can even be identified.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.